News & Updates

Use of filgrastim among lung transplant recipients (LTRs) for the treatment of neutropenia contributes to an increased burden of acute cellular rejection (ACR) and a reduced time to ACR, but not to an increased likelihood of ACR at 6 months, a study has shown.

Treatment with cytisinicline for 12 weeks, in addition to behavioural support, is well tolerated and appears to help e-cigarette users to quit vaping, according to the results of the phase II ORCA-V1 trial.

Factors such as asthma, nitrogen oxide (NO2), home remodelling history, environmental tobacco smoke (ETS), pet, mould, and age＜1 year appear to predispose children to chronic coughing, according to the results of a meta-analysis.

The investigational garsorasib, a potent KRASG12C inhibitor, appears to induce high response rate while having a manageable safety profile in patients with previously treated KRASG12C-mutated non–small cell lung cancer (NSCLC), according to the results of a phase II study.

A retrospective cohort study assessed the real-world effectiveness of nirmatrelvir/ritonavir in nonhospitalized elderly patients during transmission of Omicron sub-variants in Singapore.¹

A study compared mortality rates from COVID-19 and influenza hospitalizations during fall-winter 2023-2024.¹

Patients with sarcoidosis with heart failure (HF) appear to have an increased rate of arrhythmia at index admission, according to a recent study. In addition, sarcoidosis with HF contributes to higher hospital cost, readmission, and mortality rates relative to sarcoidosis without HF.

Treatment with sugammadex for the reversal of neuromuscular blockade falls short of significantly reducing the risk of postoperative pulmonary complications (PPCs) when compared with neostigmine, as shown in a recent study.